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We thank Drs Serrano-Martinez and Martinez-Gonzalez for their comments concerning our recently published study. They point to limitations that are an inherent part of a clinical randomized trial in a population under other behavioural influences and treatments.
We fully agree that for both dietary oleic acid and ALA, there is large evidence of potential beneficial effects in the pathogenesis and progression of atherosclerosis and relevant biomarkers. However, our goal was to assess the impact of an intensified dietary approach, which emphasizes a Mediterranean diet in a pragmatic way -namely in a medically treated patient sample of a non-Mediterranean region. In this setting, we could not find an effect of our dietary programme on markers of inflammation and metabolic risk, which, at least, implicates that a clinical relevant effect will not be easy to obtain in such populations.
Drs Serrano-Martinez and Martinez-Gonzalez rightly point to the limitation that the education may have failed in some regards and, to the contrary, the control group may have also changed their diet. Of note, subtotal adherence and restriction are not only an inherent part of clinical trials but also a problematic part of the real-life scenario in treating and advising patients. On the other hand, correlation analysis of the whole study population also revealed no associations between the diet and the measured biomarkers.
As already expressed in the article, our results do not preclude beneficial effects of the Mediterranean diet on the measured markers. The Mediterranean diet still should be regarded as an effective tool for primary and secondary prevention in coronary artery disease. However, to give the medically treated coronary patient an estimate of its current clinical impact, further studies seem necessary.
